Study of HRS-6209 combinations for breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new drug called HRS-6209 combined with other treatments for people with breast cancer that has worsened after previous therapy. It aims to find a more effective way to control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- Your cancer has gotten worse during or after your last treatment.
- You have at least one tumor that can be measured on a scan (outside the brain).
- You are willing to use effective birth control (if you could become pregnant) and are not pregnant or breastfeeding.
- You do not have serious heart problems, active infections, or certain other medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests HRS-1358 tablets in people with breast cancer that is locally advanced or has spread. It may help learn whether the drug can control cancer, while also checking safety and how the body handles it.
This trial tests a new drug, HRS-6209, combined with other treatments for people with hormone receptor-positive, HER2-negative cancer. The goal is to see if the combination is safe and works well.
This trial tests a new oral drug (HRS-8080) against standard hormone therapy for women with intermediate- or high-risk early breast cancer who have already completed 2 to 5 years of hormone treatment. It aims to see if the new drug can reduce the risk of cancer coming back.
This trial tests a combination of new drugs (HRS-8080, SHR-A2009, or others) for people with advanced breast cancer that has stopped responding to previous treatments. The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
This trial tests a new combination of drugs (HRS-8080 and dalpiciclib) for women with advanced or metastatic breast cancer that has stopped responding to initial hormone therapy after surgery. It aims to see if this combination is safe and effective.
This trial tests a new drug, HRS-7058, combined with other anti-cancer drugs for people with advanced solid tumors that cannot be surgically removed. The goal is to see if the combination can shrink tumors or slow their growth.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.